475 related articles for article (PubMed ID: 20507732)
21. [Effect of CIK on long-term survival in the treatment of HCC after RFA combined TACE].
Pan GZ; Xu JB; Hao L; Zhang J; Li SL; Yuan QZ
Zhonghua Yi Xue Za Zhi; 2016 Mar; 96(9):689-92. PubMed ID: 27055505
[TBL] [Abstract][Full Text] [Related]
22. Irregular vascular pattern by contrast-enhanced ultrasonography and high serum Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma.
Takada H; Tsuchiya K; Yasui Y; Nakakuki N; Tamaki N; Suzuki S; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Asahina Y; Enomoto N; Izumi N
Cancer Med; 2016 Nov; 5(11):3111-3120. PubMed ID: 27748052
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma.
Endo K; Kuroda H; Oikawa T; Okada Y; Fujiwara Y; Abe T; Sato H; Sawara K; Takikawa Y
Scand J Gastroenterol; 2018 Dec; 53(12):1575-1583. PubMed ID: 30577723
[TBL] [Abstract][Full Text] [Related]
24. Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
Hiraoka A; Ishimaru Y; Kawasaki H; Aibiki T; Okudaira T; Toshimori A; Kawamura T; Yamago H; Nakahara H; Suga Y; Azemoto N; Miyata H; Miyamoto Y; Ninomiya T; Hirooka M; Abe M; Matsuura B; Hiasa Y; Michitaka K
Oncology; 2015; 89(3):167-74. PubMed ID: 25999038
[TBL] [Abstract][Full Text] [Related]
25. [Comparison of safety and efficacy for transcatheter arterial chemoembolization alone and plus radiofrequency ablation in the treatment of single branch portal vein tumor thrombus of hepatocellular carcinoma and their prognosis factors].
Zhao M; Wang JP; Li W; Huang ZL; Zhang FJ; Fan WJ; Zhang L; Li XS; Pan CC; Wu PH
Zhonghua Yi Xue Za Zhi; 2011 May; 91(17):1167-72. PubMed ID: 21756768
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Tumor Response Using Alpha-fetoprotein and Des-gamma-carboxy Prothrombin in Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
Cerban R; Ester C; Iacob S; Paslaru L; Dumitru R; Grasu M; Constantin G; Popescu I; Gheorghe L
Chirurgia (Bucur); 2018; 113(4):524-533. PubMed ID: 30183583
[TBL] [Abstract][Full Text] [Related]
27. Curative effect of transcatheter arterial chemoembolization combined with radiofrequency ablation in treating hepatic cell carcinoma and its effect on serum markers.
Jiang FQ; Lu W; Yang C; Du P; Ma JP; Yang J; Xie P; Zhang Z
Cancer Biomark; 2017 Jul; 20(1):17-22. PubMed ID: 28582848
[TBL] [Abstract][Full Text] [Related]
28. Radiofrequency Ablation (RFA) Combined with Transcatheter Arterial Chemoembolization (TACE) for Patients with Medium-to-Large Hepatocellular Carcinoma: A Retrospective Analysis of Long-Term Outcome.
Liu W; Xu H; Ying X; Zhang D; Lai L; Wang L; Tu J; Ji J
Med Sci Monit; 2020 Jul; 26():e923263. PubMed ID: 32667906
[TBL] [Abstract][Full Text] [Related]
29. Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy.
Chung GE; Kim W; Lee JH; Kim YJ; Yoon JH; Lee JM; Lee JY; Kim SH; Kim D; Lee HS
J Gastroenterol Hepatol; 2011 Nov; 26(11):1638-45. PubMed ID: 22011297
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data.
Yoon JS; Song BG; Lee JH; Lee HY; Kim SW; Chang Y; Lee YB; Cho EJ; Yu SJ; Sinn DH; Kim YJ; Lee JH; Yoon JH
BMC Cancer; 2019 May; 19(1):523. PubMed ID: 31151419
[TBL] [Abstract][Full Text] [Related]
31. [Identification of immunological effector cells after autologous cytokine-induced killer cells treatment and its clinical implication in hepatocellular carcinoma patients].
Shi M; Zhang B; Tang ZR; Lei ZY; Wang HF; Feng YY; Liu JC; Fan ZP; Li HW; Mu JS; Wang FS
Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2049-53. PubMed ID: 14703414
[TBL] [Abstract][Full Text] [Related]
32. Transcatheter Arterial Chemoembolization Combined with Simultaneous Computed Tomography-guided Radiofrequency Ablation for Large Hepatocellular Carcinomas.
Zuo TY; Liu FY; Wang MQ; Chen XX
Chin Med J (Engl); 2017 Nov; 130(22):2666-2673. PubMed ID: 29133753
[TBL] [Abstract][Full Text] [Related]
33. Effect of pre- and post-treatment α-fetoprotein levels and tumor size on survival of patients with hepatocellular carcinoma treated by resection, transarterial chemoembolization or radiofrequency ablation: a retrospective study.
Toro A; Ardiri A; Mannino M; Arcerito MC; Mannino G; Palermo F; Bertino G; Di Carlo I
BMC Surg; 2014 Jul; 14():40. PubMed ID: 24993566
[TBL] [Abstract][Full Text] [Related]
34. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients.
Pan K; Li YQ; Wang W; Xu L; Zhang YJ; Zheng HX; Zhao JJ; Qiu HJ; Weng DS; Li JJ; Wang QJ; Huang LX; He J; Chen SP; Ke ML; Wu PH; Chen MS; Li SP; Xia JC; Zeng YX
Ann Surg Oncol; 2013 Dec; 20(13):4305-11. PubMed ID: 23892527
[TBL] [Abstract][Full Text] [Related]
35. Role of radiofrequency ablation in patients with hepatocellular carcinoma who undergo prior transarterial chemoembolization: long-term outcomes and predictive factors.
Sohn W; Choi MS; Cho JY; Gwak GY; Paik YH; Lee JH; Koh KC; Paik SW; Yoo BC
Gut Liver; 2014 Sep; 8(5):543-51. PubMed ID: 25071073
[TBL] [Abstract][Full Text] [Related]
36. High number of PD-1 positive intratumoural lymphocytes predicts survival benefit of cytokine-induced killer cells for hepatocellular carcinoma patients.
Chang B; Shen L; Wang K; Jin J; Huang T; Chen Q; Li W; Wu P
Liver Int; 2018 Aug; 38(8):1449-1458. PubMed ID: 29356308
[TBL] [Abstract][Full Text] [Related]
37. Clinical efficacy of DC-CIK combined with sorafenib in the treatment of advanced hepatocellular carcinoma.
Zhou Z; Qin H; Weng L; Ni Y
J BUON; 2019; 24(2):615-621. PubMed ID: 31128014
[TBL] [Abstract][Full Text] [Related]
38. CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma.
Pan QZ; Liu Q; Zhou YQ; Zhao JJ; Wang QJ; Li YQ; Tang Y; Gu JM; He J; Chen SP; Weng DS; Xia JC
Cancer Immunol Immunother; 2020 May; 69(5):825-834. PubMed ID: 32060687
[TBL] [Abstract][Full Text] [Related]
39. Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization.
Arai T; Kobayashi A; Ohya A; Takahashi M; Yokoyama T; Shimizu A; Motoyama H; Furusawa N; Notake T; Kitagawa N; Sakai H; Imamura H; Kadoya M; Miyagawa S
Int J Clin Oncol; 2014 Oct; 19(5):871-9. PubMed ID: 24218280
[TBL] [Abstract][Full Text] [Related]
40. Higher Ratio of Serum Alpha-Fetoprotein Could Predict Outcomes in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma and Normal Alanine Aminotransferase.
Kim YI; Kim HS; Park JW
PLoS One; 2016; 11(6):e0157299. PubMed ID: 27304617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
